Articles tagged "Plasmapheresis"

2022 American Transplant Congress
Treatment Modality and Outcomes of Antibody-Mediated Rejection in Pediatric Kidney Transplant Recipients: The PARAMOUr Study
R. Engen¹, A. Jain², N. Hayde³, A. Mansuri⁴, M. Kallash⁵, S. McEwen⁶, R. Garro⁷, C. Peterson⁸, R. Zahr⁹, L. Harshman¹⁰, D. Puliyanda¹¹, S. Solomon¹², K. Twombley¹³, I. Ashoor¹⁴
¹Pediatrics, University of Wisconsin Madison, Madison, WI, ²Wayne State University, Detroit, MI, ³Albert Einstein College of Medicine, New York, NY, ⁴Augusta University, Augusta, GA, ⁵The Ohio State University, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Emory University, Atlanta, GA, ⁸University of Utah Health, Salt Lake City, UT, ⁹The University of Tennessee Health Science Center, Memphis, TN, ¹⁰University of Iowa, Iowa City, IA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²New York Medical College, Valhalla, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Louisiana State University, New Orleans, LA
*Purpose: Antibody-mediated rejection (AMR) is the leading cause of graft failure in kidney transplantation, but evidence for effective treatments is limited.*Methods: PARAMOUr is a retrospective…
2022 American Transplant Congress
Two Times or More Double-Filtration Plasmapheresis Increases the Risk of Bleeding During Kidney Transplantation
T. Kanzawa, T. Tagisawa, M. Furusawa, K. Unagami, K. Kitajima, K. Omoto, H. Ishida, K. Tanabe, T. Takagi
Urology, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Double-filtration plasmapheresis (DFPP) is effective for desensitization in ABO incompatible and highly sensitized transplantation. In such cases, bleeding is difficult to stop due to…
2022 American Transplant Congress
Excellent Long-Term Outcome of ABO-Incompatible Living Kidney Transplantation by Reduced-Session of Plasmapheresis of Desensitization Protocol
Y. Ishiyama¹, K. Tanabe², T. Kanzawa², K. Unagami², H. Ishida², T. Takagi²
¹Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan, ²Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Plasmapheresis (PE) is applied to ABO-incompatible living kidney transplantation (ABOi-LKT) in order to remove ABO blood type antibody to obtain the appropriate target levels.…
2022 American Transplant Congress
Outcomes of Post-Operative Plasmapheresis in African American Kidney Transplant Recipients with High Panel Reactive Antibodies – A Single Center Experience
B. Valdepenas, M. Campara, J. Benken, C. Muran, D. Pierce, K. Heagler, P. DiCocco, J. Almario Alvarez, M. Spaggiari, I. Tang, I. Tzvetanov, E. Benedetti
University of Illinois at Chicago, Chicago, IL
*Purpose: African American (AA) kidney transplant (KTx) candidates are disadvantaged given increased immunologic risk and longer waitlist time. The purpose of this study was to…
2022 American Transplant Congress
Impact of the High Baseline Anti-a/b Antibody Titer on the Clinical Outcomes in ABO-incompatible Living Donor Liver Transplantation
J. Cho, B. Lee, H. Lee
Surgery, Seoul National Bundang Hospital, Seongnam, Korea, Republic of
*Purpose: Recently, advances in desensitization protocol have made ABO-incompatible (ABOi) living donor liver transplantation (LDLT) feasible option in the era of organ shortage. Although, multiple…
2022 American Transplant Congress
Plasmapheresis Dependent AT1R Antibody Associated Recurrent FSGS After Living Donor Kidney Transplantation
R. K. Mallavarapu
Transplant Nephrology, Augusta University - Medical College of Georgia, Augusta, GA
*Purpose: Antibodies against Angiotensin II type 1 receptors (AT1R-Abs) may predispose to podocyte injury, glomerular endotheliosis and proteinuria. The management of AT1R-Ab associated recurrent FSGS…
2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²
¹MedStar Georgetown University Hospital, Washington, DC, ²Temple University Hospital, Philadelphia, PA
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…
2021 American Transplant Congress
A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
Y. Caliskan¹, H. Yazici², A. B. Dirim², E. Aksoy², S. Safak², N. Garayeva², S. Mirioglu², O. Yegit², O. A. Oto², Y. Ozluk³, S. Besisik⁴, A. Turkmen², K. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²Division of Nephrology, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University, Istanbul, Turkey, ⁴Division of Hematology, Istanbul University, Istanbul, Turkey
*Purpose: Effective management to prevent allograft loss after late antibody mediated rejection (ABMR) in kidney transplant (KTx) recipients remains a vexing clinical challenge. While plasma…
2021 American Transplant Congress
Weathering the Cytokine Storm: Therapeutic Plasma Exchange for the Management of Severe Covid19 in Solid Organ Transplant Recipients
A. Mattiazzi¹, J. Pagan¹, L. A. Mendez Castaner², A. Fernandez¹, R. Zamora Gonzalez¹, J. Simkins¹, L. Preczewski¹, Y. Natori¹, S. Anjan¹, G. Guerra¹
¹Miami Transplant Institute, Miami, FL, ²Miami Trasnplant Institute, Miami, FL
*Purpose: The treatment of SARS-CoV-2 associated pneumonia in solid organ transplant recipients (SOTr) continues to be under investigation. Timely control of the cytokine release storm…
2021 American Transplant Congress
Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
A. Al Jurdi¹, L. Goldfarb¹, M. Lafargue², J. Azzi³, L. V. Riella¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²Université de Paris, Paris, France, ³Transplantation Research Center, Brigham and Women’s Hospital, Boston, MA
*Purpose: The optimal regimen for treating acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients has yet to be established. The purpose of the…

1
2
3
…
6
Next Page »